Law360, New York (October 03, 2007, 12:00 AM ET) -- Eli Lilly & Co. is seeking to stay a whistleblower suit over charges it marketed its blockbuster anti-psychotic drug Zyprexa for off-label uses, arguing the case should be joined with a multidistrict product liability litigation pending in a New York district court.
In court documents filed Wednesday in the U.S. District Court for the Northern District of California, Lilly said the action raises many issues that are already the subject of ongoing multidistrict proceedings in the U.S. District Court for the Eastern District of New York....
Lilly Seeks To Stay Whistleblower Suit Over Zyprexa
To view the full article, take a free trial now.
